Skip to main navigation Skip to search Skip to main content

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

  • Martin van den Bent
  • , B Baumert
  • , SC Erridge
  • , MA Vogelbaum
  • , AK Nowak
  • , M Sanson
  • , AA Brandes
  • , PM Clement
  • , JF Baurain
  • , WP Mason
  • , H Wheeler
  • , OL Chinot
  • , S Gill
  • , M Griffin
  • , DG Brachman
  • , Walter Taal
  • , R Ruda
  • , M Weller
  • , C McBain
  • , J Reijneveld
  • RH Enting, DC Weber, T Lesimple, S Clenton, A van Gijtenbeek, S Pascoe, U Herrlinger, P Hau, F Dhermain, I Heuvel, R Stupp, K Aldape, RB Jenkins, Erik jan Dubbink, Winand Dinjens, P Wesseling, S Nuyens, V Golfinopoulos, T Gorlia, W Wick, J.M. Kros

Research output: Contribution to journal › Article › Academic › peer-review

344 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1645-1653
Number of pages9
JournalLancet (UK)
Volume390
Issue number10103
DOIs
Publication statusPublished - 2017

Research programs

  • EMC OR-01

Cite this